Table 1.
Demographics of the sampled data set.
| Demographic | HCC (n=9553) | Control (n=38,392) | Difference | ||||
| Age (years), mean (SD) | 59.9 (14) | 47.5 (17.3) | N/A | ||||
| Male, n (%) | 6175 (64.6) | 18489 (48.2) | N/A | ||||
| ICD-9a, mean diagnoses per patient in 3 years (ordered by difference) | |||||||
|
|
Total | 126.2 | 78.1 | 48.1 | |||
|
|
571 (Chronic liver disease and cirrhosis) | 8.36 | 0.61 | 7.75 | |||
|
|
250 (diabetes mellitus) | 6.23 | 2.27 | 3.96 | |||
|
|
070 (viral hepatitis) | 3.19 | 0.3 | 2.89 | |||
|
|
401 (essential hypertension) | 5.43 | 2.83 | 2.59 | |||
|
|
465 (acute upper respiratory infections) | 5.37 | 3.63 | 1.73 | |||
|
|
780 (general symptoms) | 4.16 | 2.43 | 1.73 | |||
|
|
533 (peptic ulcer) | 1.93 | 0.55 | 1.38 | |||
|
|
372 (disorders of conjunctiva) | 2.78 | 1.59 | 1.19 | |||
|
|
724 (disorders of back) | 2.38 | 1.22 | 1.17 | |||
|
|
402 (hypertensive heart disease) | 1.89 | 0.76 | 1.12 | |||
| ATCb code, mean prescribed days per patient in 3 years (ordered by difference) | |||||||
|
|
Total | 2362 | 1099 | 1263 | |||
|
|
A05BA (liver therapy) | 97.87 | 5.8 | 92.08 | |||
|
|
A10BB (blood glucose–lowering drugs) | 93.51 | 29.88 | 63.63 | |||
|
|
C08CA (selective calcium channel blockers with vascular effects) | 119.37 | 60.93 | 58.44 | |||
|
|
A10BA (blood glucose–lowering drugs) | 77.87 | 32.36 | 45.51 | |||
|
|
B01AC (platelet aggregation inhibitors) | 87.12 | 45.71 | 41.42 | |||
|
|
N05BA (benzodiazepine, for anxiolytics) | 71.18 | 34.29 | 36.89 | |||
|
|
A02AX (antacids for acid related disorders) | 42.61 | 14.68 | 27.93 | |||
|
|
C07AB (beta=blocking agents, cardiovascular system) | 58.82 | 31.39 | 27.43 | |||
|
|
C09AA (ACEc inhibitors, cardiovascular system) | 42.13 | 15.36 | 26.77 | |||
|
|
A02AF (antacids with antiflatulents) | 27.91 | 2.06 | 25.84 | |||
aICD-9: International Classification of Disease, Ninth Revision.
bATC: Anatomical Therapeutic Chemical (classification system).
cACE: angiotensin-converting enzyme.